Work

Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel

Year: 2022

Type: article

Study design: Observational Study

Source: International Journal of Clinical Oncology

DOI: 10.1007/s10147-022-02203-y

Authors: Shintaro Narita, Takahiro Kimura, Shingo Hatakeyama, Kenichi Hata, Takafumi Yanagisawa, Shinya Maita, Shuji Chiba, Hiromi Sato, Soki Kashima, Atsushi Koizumi, Ryohei Yamamoto, Koichiro Takayama, Katsumi Okane, Toshiya Ishida, Yohei Horikawa, Teruaki Kumazawa, Jiro Shimoda, Takehiro Suzuki, Chikara Ohyama, Shin Egawa, Tomonori Habuchi

Institutions: Akita University, Akita University Hospital, Jikei University School of Medicine, Hirosaki University, Atsugi City Hospital, Iwate Prefectural Isawa Hospital, Yuri Kumiai General Hospital, Akita Kousei Medical Center, Akita City Hospital, Akita Red Cross Hospital, Omagari Kousei Medical Center, Hiraka General Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Japan Society for the Promotion of Science

Award: Development of molecular targeted boron neutron capture therapy

OpenAlex ID: W4283372952

FWCI: 0.698

Cites: 36

Cited by: 13

Related to: 10